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Genomic analysis of oesophageal squamous-cell
carcinoma identifies alcohol drinking-related
mutation signature and genomic alterations
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Approximately half of the world’s 500,000 new oesophageal squamous-cell carcinoma
(ESCC) cases each year occur in China. Here, we show whole-genome sequencing of DNA
and RNA in 94 Chinese individuals with ESCC. We identify six mutational signatures (E1–E6),
and Signature E4 is unique in ESCC linked to alcohol intake and genetic variants in alcohol-
metabolizing enzymes. We discover significantly recurrent mutations in 20 protein-coding
genes, 4 long non-coding RNAs and 10 untranslational regions. Functional analyses show
six genes that have recurrent copy-number variants in three squamous-cell carcinomas
(oesophageal, head and neck and lung) significantly promote cancer cell proliferation,
migration and invasion. The most frequently affected genes by structural variation are
LRP1B and TTC28. The aberrant cell cycle and PI3K-AKT pathways seem critical in ESCC.
These results establish a comprehensive genomic landscape of ESCC and provide potential
targets for precision treatment and prevention of the cancer.
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O
esophageal squamous-cell carcinoma (ESCC) ranks the
fourth leading cause of cancer death and approximately
half of the world’s 500,000 new ESCC cases each year
occur in China1,2. Epidemiological studies have suggested that
alcohol intake, tobacco smoking, micronutrient deficiency and
dietary carcinogen exposure may cause ESCC3–5. However, the
mutational signatures in ESCC associated with lifestyle or
environmental aetiological factors have not been explored. There
are currently no specific molecule-targeting agents for ESCC
treatment and therefore the long-term outcome of this cancer is
still dismal, with 5-year survival rate around 30% (refs 6,7).
Several studies on whole-exome sequencing (WES) in ESCC in
Chinese and Japanese populations have been published recently.
These studies reported an extremely high frequency of TP53
mutations and low prevalence but statistically significant single-
nucleotide variations (SNVs) in several other genes, including
CDKN2A, NOTCH1, RB1 and PIK3CA8–15. All these WES studies
only took into account somatic variations in the protein-coding
regions; however, the protein-coding components of the genome
account for onlyB2% of the total sequences and previous studies
indicated that the non-coding regions are more frequently
affected by mutations compared with the coding regions16.
The effects of the non-coding variations on ESCC development
have not been characterized at the whole-genome level. Although
both copy-number variations (CNVs) and structural variations
(SVs) in ESCC have been reported, the results were based on low-
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Figure 1 | Genome-wide mutational signatures of 704 ESCC samples. (a) The whole-exome mutation spectra. Colours represent the six SNV types on
the upper right. The three base content of each mutation is labelled in the 44 legend on the lower right. ESCC show an enrichment for APOBEC-mediated
C4G and C4T mutations of C4G and C4T in TpCpW trinucleotide sites (where W corresponds to either A or T). (b) Patterns of substitutions for
Signatures E1–E6. Each signature is displayed according to the 96 substitution classifications defined by the substitution class and sequence context
immediately 50 and 30 to the mutated base. The vertical axis represents mutation fractions of each substitution classification. (c) The contributions of
mutational signatures to individual ESCC samples. Each bar represents a selected sample from the 704 ESCC samples. The horizontal axis denotes 704
ESCC samples and the vertical axis denotes the number of mutations (upper panel) or mutation fractions (lower panel). (d) Number of mutations in each
signature (left panel) and total number of mutation (right panel) as function of drinking status. The data represent median and interquartile range and
P values are from unpaired Wilcoxon rank-sum test. NS, not significant. (e,f) Number of mutations in Signature E4 as function of ALDH2 or ADH1B
genotypes in Chinese (e) or Japanese (f) ESCC samples. Data are displayed in Tukey’s boxplot. The line in the middle of the box is plotted at the median
while the upper and lower hinges indicated 25th and 75th percentiles. Whiskers indicate 1.5 times interquartile range (IQR) and values greater than it are
plotted as individual points. The minima and maxima are the lowest datum still within 1.5 IQR of the lower quartile and the highest datum still within 1.5 IQR
of the upper quartile. Unpaired Wilcoxon rank-sum test were used. NS, not significant.
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coverage whole-genome sequencing (WGS) and/or single-
nucleotide polymorphism (SNP) array with relatively small
sample size9–15,17. The apparent limitations in the previous
studies warrant performing more comprehensive studies.
Here we report an integrated analysis of genomic signatures,
SNVs, CNVs, SVs and their correlations with mRNA expression
in ESCC from Chinese individuals. We have comprehensively
characterized the genomic landscape features in ESCC that may
provide clues to environmental aetiological factors and identified
potential targets that may guide to develop precision treatment
and prevention of this malignancy.
Results
WGS of ESCC samples. We collected tumours, distant normal
tissues, peripheral blood samples and clinical information
from 94 individuals with ESCC (Supplementary Fig. 1 and
Supplementary Data 1). WGS of the tumour and blood samples
was performed and mutational signatures, SNVs, CNVs and SVs
were analysed. In addition, we performed RNA sequencing of all
ESCC and distant normal tissues. The mean coverage of WGS
was 56 for tumour with 94% of bases 430 and 36 for
matched blood samples with 93% of bases 420 , respectively
(Supplementary Data 2). In all, WGS identified 617,629 SNVs,
55,453 indels, 57 focal CNV regions and 6,844 SVs
(Supplementary Fig. 2a,b).
We found a genome-wide mutation rate of 2.1 mutations per
megabase (Mb). There were 6,797 (1.1%) SNVs or indels with
1.98 mutations per Mb in the protein-coding regions and 610,832
(98.9%) SNVs or indels with 2.13 mutations per Mb in the non-
coding regions, respectively (Supplementary Fig. 2a). The amount
of SNVs was positively associated with mutational status of TP53
(P¼ 1.34 10 4, unpaired t-test; Supplementary Table 1). We
found that 9.6% (9/94) of ESCC samples had occasional kataegis
loci (range¼ 1–3), which are localized substitution hypermuta-
tions and associated with genomic rearrangement, and 4 of
these kataegis had SVs nearby (Supplementary Fig. 2c and
Supplementary Table 2). We counted the number of SNVs in the
matrix of 96 possible mutations occurring in a trinucleotide
context in each ESCC sample and found that the predominant
mutations were the C4T and C4G transitions at TpCpW
trinucleotide sites (Fig. 1a), which is similar to the signature of
APOBEC enzyme family-mediated mutagenesis18.
The mutational signatures of ESCC. Mutational signatures in
cancer genome might reflect and trace DNA damage caused by
DNA-damaging agents to which cells have been exposed. How-
ever, the previous WES studies did not address this important
issue in ESCC probably due to the limited statistical power.
In this study, we combined our WGS data with WES data
obtained from published studies9,11–15 including 94 ESCC
samples from The Cancer Genome Atlas (TCGA) database to
increase sample size to 704 for analysing SNV profile in the
protein-coding regions. By using 1,000 iterations of non-negative
matrix factorization19, we identified six mutational signatures
(Signatures E1–E6) in ESCC that are of high stability and low
reconstruction error (Supplementary Fig. 3).
We then performed cosine similarity analysis to compare the
mutational signatures in ESCC with current Catalogue of Somatic
Mutations in Cancer (COSMIC)19 (Supplementary Table 3) and
found that five ESCC signatures are highly similar to COSMIC
signatures. Signature E1 is highly similar to COSMIC Signatures 2
and 13 (cosine similarity 0.819 and 0.813, respectively), which is
believed to be due to over activity of the APOBEC, a family of
cytidine deaminases. APOBEC enzymes convert cytidine to uracil
that is usually coupled with the activities of base excision repair
and DNA replication machineries20. In our samples, the
expression levels of APOBEC3B and APOBEC3C were
significantly higher in tumours than in paired normal tissues
(P¼ 8.81 10 31 and P¼ 3.21 10 5, respectively, unpaired
t-test; Supplementary Fig. 2d) and strongly correlated with the
total number of the C4T (P¼ 0.022, Spearman’s r¼ 0.24) and
C4G (P¼ 0.019, Spearman’s r¼ 0.24) mutations at TpCpW
trinucleotide sites, respectively (Supplementary Fig. 2d). Signature
E2 showed high similarity to COSMIC Signature 4 (cosine
similarity 0.860), which was previously identified to be associated
with smoking status in lung cancer patients19. This signature is
only significantly associated with individuals’ smoking status in
our 94 ESCC samples (P¼ 0.027, unpaired Wilcoxon rank-sum
test; Supplementary Fig. 4c) but not in other WES studies
(Supplementary Fig. 4b,c). Signature E3 (cosine similarity 0.829
and 0.783) and Signature E5 (cosine similarity 0.838 and 0.892)
are highly similar to COSMIC Signatures 1A and 1B, both of
which were identified as age-dependent mutational signatures
(Supplementary Table 3). Signature E3 and Signature E5 were
both associated with age at diagnosis of 699 ESCC who had
information on age (P¼ 3.20 10 4 and P¼ 0.006, unpaired
Wilcoxon rank-sum test; Supplementary Fig. 4a). We found that
the average percentage of the T4C mutation per sample was
significantly higher in drinkers (13.6%) than in non-drinkers
(9.7%; P¼ 3.60 10 10, unpaired t-test) and Signature E4,
specifically characterized by the T4C mutation, is similar to
COSMIC Signature 16 (cosine similarity 0.873) of which the
origin was unknown before. In the present study, we identified
Signature E4 significantly associated with individuals’ smoking
and drinking status (P¼ 0.002 and P¼ 9.69 10 28, unpaired
Wilcoxon rank-sum test; Fig. 1d and Supplementary Fig. 4b). Our
previous genome-wide association studies have identified two
functional SNPs, rs671 in ALDH2 on 4q23 and rs1229984 in
ADH1B on 12q24, that are significantly associated with the risk of
ESCC in a manner of interactions with alcohol drinking and
tobacco smoking status21,22. Therefore, we further analysed the
mutation profiles in the function of ALDH2 and ADH1B
genotypes. We found that the frequency of Signature E4
mutations in ESCC from drinkers with the risk ALDH2
genotype (rs671-AG/-AA) was significantly higher than that in
ESCC from drinkers with the non-risk genotype (rs671-GG;
P¼ 0.003, unpaired Wilcoxon rank-sum test). It was also
significantly higher than that in ESCC from non-drinkers with
the rs671-AG/-AA genotype (P¼ 0.006, unpaired Wilcoxon rank-
sum test) or ESCC from non-drinkers with the rs671-GG
genotype (P¼ 0.001, unpaired Wilcoxon rank-sum test)
(Fig. 1e). The significant differences between the frequencies of
Signature E4 mutations were also seen when the analysis was
stratified by the ADH1B rs1229984 genotypes (Fig. 1e).
Interestingly, the similar results were also observed in ESCC in
Japanese14, whose ALDH2 and ADH1B genotype data are
available (Fig. 1f). We also found that individuals with
Signature E4 mutations had significant transcriptional strand
bias for the T4C change (Supplementary Fig. 5), which is
believed to be caused by the differences in repair efficiency of
DNA damage and maintenance processes between transcribed
and untranscribed strands of genes19. Signature E6 (Fig. 1b),
characterized specifically by the T4A and T4G mutations,
showed low similarity to any of the COSMIC signatures
(all cosine similarity o0.8) and appears to be a new mutational
signature in ESCC.
Recurrent mutations in the protein-coding genes. We obtained
6,184 SNVs and 613 indels in the exonic regions of 94 ESCC
samples (Supplementary Data 3); 72% of these mutations were
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expressed and 41, 46 and 53% mutations were confirmed if the
locus has at least 10, 5 and 1 read/s, respectively, with the mutant
nucleotide by RNA sequencing. In addition, we selected 105
putative somatic mutations for further validation and 95 (90.5%)
selected mutations were confirmed by PCR-based Sanger
sequencing. Using the MutSigCV23, we identified six significantly
mutated genes, including CDKN2A, TP53, NOTCH1, FBXW7,
NFE2L2 and AJUBA (all false discovery rate (FDR) qo0.5;
Supplementary Fig. 6). All of them have previously been reported
in ESCC and two other types of squamous cell carcinomas, head
and neck squamous cell carcinomas (HNSCC) and lung
squamous cell carcinomas (LUSCC) (Supplementary Data 4).
To increase the statistical power to detect the driver mutations,
we analysed the data in combined sample of 704 ESCC, which
provides 90% power to detect genes mutated in 2% individuals24.
As a result, we detected 20 putative driver genes and found
that 93% (657/704) of ESCC had at least one somatic mutation
in these genes (Fig. 2 and Supplementary Figs 7 and 8).
Recapitulating previous reports, we confirmed mutations in 12
genes, including MLL2, FAT1, PIK3CA, EP300, ZNF750,
CREBBP, NOTCH3, PTCH1, RB1, KDM6A, TGFBR2 and PTEN.
Furthermore, we identified two novel mutated genes, CUL3 and
RBPJ, in ESCC (Fig. 2 and Supplementary Data 4). We found that
knockdown of CUL3 or RBPJ significantly promoted malignant
phenotypes of ESCC cells such as proliferation, migration and
invasion; but overexpression of these genes significantly
suppressed these malignant phenotypes (Supplementary Fig. 9).
In addition, we observed that the rate of PTCH1 mutation was
significantly higher in ESCC in smokers compared with that in
nonsmokers (P¼ 0.030, one-sided Fisher’s exact test), while the
rates of TP53, EP300, PTCH1, NOTCH3, TGFBR2 and ZNF750
mutations were significantly higher in ESCC in drinkers than that
in non-drinkers (all Po0.05, one-sided Fisher’s exact test). ESCC
at late stage had significantly more NOTCH1 mutations
compared with ESCC patients at early stage (P¼ 0.001, one-
sided Fisher’s exact test; Supplementary Data 5).
We then compared the mutational profiles in ESCC, HNSCC,
LUSCC or oesophageal adenocarcinoma (EAC) and found that
the 20 genes significantly mutated in ESCC were also frequently
mutated in HNSCC and LUSCC; however, in EAC, only TP53,
CDKN2A and PIK3CA were frequently mutated (Supplementary
Data 4). Clustering analysis showed that the mutational profile of
ESCC is similar to HNSCC and LUSCC but dissimilar to EAC
(Supplementary Fig. 10). These results indicate that cancers
originated from the same cell type might have the same driver
mutations but cancers in the same organ generated from different
cell type might have distinct driver mutations, reflecting different
aetiology and the molecular mechanisms of pathogenesis15,25.
Recurrent mutations in the non-coding elements. We next
analysed the mutations in the non-coding regions, including the
gene promoters, untranslated regions (UTRs) and long non-
coding RNAs (lncRNAs) annotated by GENCODE v24 (ref. 26).
Using the regional recurrence testing approach16, we found 15
regions that had significantly higher mutation rates than
that expected by chance (qo0.05; Supplementary Table 4 and
Supplementary Fig. 11), including 4 lncRNAs (NEAT1,
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LINC01360, PART1 and CTA-280A3.2), 1 promoter (FCMR) and
10 UTRs (SMAD2, YIPF4, ZNF605, FOXJ3, NABP1, CLOCK,
YTHDC1, TMEM178B, TNFRSF11A and GALR1). For instance,
6.4% ESCC samples had mutations in NEAT1, an lncRNA that is
associated with malignant phenotypes of several types of cancer
including ESCC27–30. By integrating analysis of WGS and RNA
sequencing data, we found that the mutations in the 30UTR of
FOXJ3 were significantly correlated with the overexpression of
this gene, whereas the mutations in the 30UTR of CLOCK were
significantly associated with downregulation of this gene
(Supplementary Fig. 12).
Whole-genome copy-number alterations. We found that 97.9%
(92/94) of ESCC had CNVs at chromosome arm level, including
loss at 3p, 4p, 4q, 5q, 9p, 13q, 18q and 21p and gain at 3q, 5p, 7p,
8q, 12p, 16p, 20p and 20q (Fig. 3a). These CNV profiles resemble
those in HNSCC and LUSCC but differ from those in EAC and
stomach adenocarcinoma (STAD, Supplementary Fig. 13a,b).
Through additional cluster analysis of RNA expression data, we
found that the RNA expression pattern in ESCC is also similar to
that in HNSCC and LUSCC but differs from that in EAC and
STAD (Supplementary Fig. 13c,d). The similar SNV and CNV
profiles along with the similar RNA expression pattern support
that ESCC belongs to the ‘squamous’ molecular subtype as
identified by Hoadley et al.31 We also identified 23 focal regions
with recurrent gain of copy number and 34 regions with recurrent
loss of copy number (both qo0.25; Fig. 3b), in which 1,591 and
4,841 genes are involved, respectively, and many have previously
been identified as tumour-associated genes (Supplementary Data
6 and 7). Among them, five recurrent focal amplifications
(1p36.32, 1q42.13, 6p21.33, 17q21.31 and 19p13.3) and seven
recurrent focal deletions (5q13.2, 6p24.3, 10q21.1, 12q23.1,
13q31.3, 15q14 and 21q21.1) were identified for the first time
in ESCC (Supplementary Data 8).
We then retrieved these 57 focal CNV peaks and examined
whether the gene with copy-number gain or loss has substantial
effect on its mRNA expression measured by RNA sequencing.
The results showed that, among the 6,432 genes located in these
CNV regions, 538 (33.8%) with copy-number gain and 1,416
(29.3%) with copy-number loss had mRNA levels that are
significantly correlated with gene copy number (Spearman’s
r40.3 and Po0.05; Supplementary Fig. 14 and Supplementary
Data 9). Through the analysis using a gene–drug interaction
database32, we found that, among the genes that show aberrations
in DNA copy number and mRNA expression, 184 (including
EGFR, CCND1, PIK3CA and MAPK1) have the potential to
interact with at least one drug (Supplementary Data 10).
Functional characterization of genes with CNV. To identify the
causal copy-number alterations, we compared the CNV profile in
ESCC with that in HNSCC and LUSCC. We found that 14 genes
(7 with copy-number gain and 7 with copy-number loss) had
aberrant mRNA expression in all three SCCs (Spearman’s r40.3
and Po0.05; Supplementary Data 11, Supplementary Figs 15–17).
We then used a quick in vitro function screening approach to
examine whether these 14 genes have effects on malignant phe-
notypes of SCC cell lines, KYSE30 (ESCC), DaFu (HNSCC) and
NCI-H520 (LUSCC) and found that knockdown of EGFR, BRD9
or PPFIA1 expression by short interfering RNA (siRNA) resulted
in significant inhibition of cell proliferation (Fig. 3c and
Supplementary Figs 18–20). In addition, we found that knock-
down of EGFR and CLPTM1L expression significantly inhibited
migration and invasion, whereas knockdown of ATP9B or PQLC1
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Figure 3 | CNV in ESCC and functional impact of some genes with CNV. (a) CNV at arm level. The bar graphs show the frequency of arm-level
copy-number alterations and the vertical axis denotes chromosome arms. (b) CNV at focal regions detected by GISTIC 2.0. Regions of recurrent focal
amplifications (left) and focal deletions (right) are plotted by false discovery rate (x axis) for each chromosome (y axis). Annotated peaks have residual
qo0.25 andr40 genes within peak regions. These peak regions are annotated with candidate known cancer genes and the total number of genes within
these peaks are given in brackets. A dashed line represents the centromere of each chromosome. (c) The effects of knockdown by siRNA of 14 genes with
CNV on proliferation, migration and invasion of SCC cell lines KYSE30, FaDu and NCI-H520. These genes were selected for functional assays because they
were affected by CNV identified in all three types of SCC, that is, ESCC, HNSCC and LUSCC. For cell proliferation, the results are presented as mean±s.e.m.
from three independent experiments and each had three replications. For cell migration and invasion, the results are presented as mean±s.e.m. from
three independent experiments and each had duplication. The dashed line represents mean of siRNA control result. *Po0.01 compared with control by
Student’s t-test.
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significantly enhanced migration and invasion of cancer cells
(Fig. 3c and Supplementary Figs 18–20).
Whole-genome structural variations. We found 6,844 SVs in 94
ESCC samples (73 SVs per sample in average), including 3,610
(52.7%) inter-chromosomal translocations, 1,863 (27.2%) dele-
tions, 805 (11.8%) inversions and 566 (8.3%) intra-chromosomal
translocations. We also identified 13 (13.8%) chromothripsis
(Supplementary Fig. 21), the massive DNA rearrangements
resulting from the repair of localized chromosome shatters in a
one-off catastrophe33,34. Across whole genomes of 94 ESCC,
2,607 SVs with breakpoints in 257 gene regions were found in43
samples. The most frequently affected genes were LRP1B (48.9%),
a putative tumour suppressor that displays frequent deletion or
methylation in human cancer35,36 and TTC28 (31.9%), whose
recurrent chromosomal translocation was also seen in colorectal
cancer, small-cell lung cancer and liver cancer28,37,38 (Fig. 4a).
We also identified SVs in FHIT, RAD51B, MYH9 and CDKN2A
in a frequency of 45% samples (Supplementary Data 12). Since
SVs may alter gene expression due to the change of gene-
enhancer distance or alterations of gene copy number or
structure, we therefore examined the mRNA expression of
genes with or without SVs in ESCC (Fig. 4b). Interestingly, we
found 23 genes whose expression were significantly altered
by SV (Po0.05, unpaired t-test; Supplementary Data 12) and
among them were well-known cancer-related genes CDKN2A
(SV in 5 samples), PRKCA (SV in 3 samples) and EP300
(SV in 3 samples).
We further screened gene fusion events in our samples, which
were validated by PCR-based Sanger sequencing (Supplementary
Table 5). We identified ERC1 that was fused with different
partners, PRAF2,WNK1 or RAD51, respectively, in three samples.
ERC1 is a member of RIM-binding protein family that regulates
neurotransmitter release and has been shown to be fused to the
RET in papillary thyroid carcinoma39. We also detected and
validated NRG1-ZCCHC7 and WT1-MRPL19 fusions,
respectively, in two samples (Fig. 4c).
Functionally aberrant pathways in ESCC. We integrated the
above described 20 genes having driver mutations and 586 genes
with CNV into pathway analysis to identify the functionally
aberrant pathways in ESCC. We selected the genes with CNV for
the analysis based on both copy number and mRNA expression
changes in tumour tissues compared with normal tissues. As a
result, we identified a highly interconnected network of
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Figure 4 | SVs and their effects on gene expression. (a) Number of samples with at least one SV breakpoint in gene region. The vertical axis represents
chromosome positions. (b) Correlations of SV with mRNA expression of genes. The y axis denotes log-transformed P values from t-test between gene
expression of samples with and without SV. The vertical axis represents chromosome positions. (c) Validation of gene fusion in ESCC. Left, gel analysis of
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aberrations targeting the receptor tyrosine kinases (RTK/RAS/
phosphoinositide-3 kinase (PI3K)), cell cycle regulators, WNT,
NOTCH and TP53 pathways (Fig. 5, Supplementary Data 13 and 14).
Several receptor tyrosine kinases (that is, EGFR, ERBB2 and
ERBB3), their downstream signal transducer PIK3CA and other
components in the RTK/PI3K pathway exhibited recurrent focal
amplification and/or SNV. We found 14.9% (14/94) samples that
had EGFR amplification while SNV in this gene was only 1.1% (1/
94). The amplification rate for PIK3CA, a known oncogene in
many types of human cancer, was 38.3% (36/94) and only two
samples with PIK3CA amplification displayed concurrent muta-
tions. We found a significant positive correlation between
PIK3CA copy-number gain and elevated mRNA expression. The
deletion rate of PIK3R1 in our samples was 4.3% (4/94) and the
mRNA expression levels of this gene were significantly lower in
tumours than in normal tissues (P¼ 3.71 10 24, paired t-test).
We found that several genes involved in the cell cycle pathway
(for example, TP53, CDKN2A, CCND1 and MYC) were
frequently altered. P53 was mutated in 77.7% (73/94) of samples,
consistent with the previous reports8–15, while CDKN2A was
deleted or mutated in 36.2% (34/94) or 12.8% (12/94) of samples.
CCND1 and MYC were frequently amplified with a rate of 57.4%
(54/94) and 42.6% (40/94). Furthermore, we found RB1 mutation
in 2.1% (2/94) and deletion in 4.3% (4/94) of samples. Loss of
CDKN2A and/or gain of CCND1 may impair RB-mediated cell
cycle control40. CDKN2A is a tumour suppressor in the
development of squamous cell carcinoma and other types of
human cancer41,42. Cyclin D1 encoded by CCND1 can form a
complex with CDK4 and CDK6, which may lead to RB protein
phosphorylation, resulting in disruption of cell cycle restriction,
genome instability and tumorigenesis43.
In addition, we identified mutation and amplification of
NFE2L2 (also known as NRF2), a key transcriptional regulator
involved in metabolic processes and oxidative stress44, with a rate
of 7.4% (7/94) and 10.6% (10/94). We also identified CUL3
mutation and deletion in 2.1% (2/94) and 1.1% (1/94),
respectively, and CUL5 deletion in 2.1% (2/94) of samples, both
of which encode proteins that form a complex with NFE2L2 in
transcriptional regulation. Mutations in NFE2L2 may result in
increased activity of its protein and consequent deregulation of its
downstream molecules that promote tumorigenic metabolism.
We also identified mutations in NOTCH gene family, which
play important roles in SCCs45–47. We found significantly
elevated mutations in NOTCH1 (17.0% (16/94)) and NOTCH3
(5.3% (5/94)) and non-significant (q40.1) mutations in
NOTCH2 (3.2% (3/94)). Two genes encoding the epigenetic
regulators, MLL2 and CREBBP, were mutated in 13.8% (13/94)
and 5.3% (5/94) of samples and its amplification occurred with
a frequency of 1.1% (1/94) and 5.3% (5/94). FBXW7, a well-
established tumour-suppressor gene that targets various
oncogenic proteins for degradation, was mutated in 7.4% (7/94)
and deleted in 6.4% (6/94) of samples.
Discussion
Several studies on whole-exon sequencing of ESCC have recently
been published; however, the results are limited to somatic
mutations in exonic regions of protein-coding genes, the
approximately 2% of DNA sequences in human genome. In the
present study, we performed an integrative analysis of WGS and
RNA sequencing of 94 ESCC samples. Based on the systematical
analysis of whole-genome mutational signatures, SNVs, CNVs,
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SVs and mRNA expression and combined analysis with previous
WES data, we have established a more comprehensive genomic
landscape of ESCC. Several novel findings have been achieved in
this study. First, we identified six mutational signatures in ESCC
and found that Signature E4, characterized by the T4C mutation
in the transcribed strand, is associated with alcohol intake and
germline variants in two alcohol-metabolizing genes. Second, we
identified recurrent mutations in 20 protein-coding genes, among
them were CUL3 and RBPJ, two genes whose recurrent mutations
have never been reported before in ESCC. We also identified for
the first time the significant mutations in 15 non-coding regions,
including that produces lncRNA NEAT1 (refs 27–30) and 30UTR
of FOXJ3 and CLOCK. Third, we identified 57 focal regions with
recurrent CNVs and 6 genes in these regions had aberrant mRNA
expression, which significantly promoted proliferation, migration
and/or invasion of SCC cells. Furthermore, we identified that
LRP1B and TTC28 are the most frequently affected genes by
SV in ESCC. We also found frequent aberrations of cell cycle
pathway and PI3K-AKT signaling pathway in ESCC, suggesting
that these may be the most critical pathways involved in the
development and progression of ESCC.
In the present study, we combined available ESCC WES data
with our WGS results (total N¼ 704) for analysis of mutational
signatures and SNVs in coding regions9,11–15. We did not include
the first whole-exonic sequencing study8 for combined analysis
because of small sample size of only 12 ESCC. Using combined
analysis with increased sample size, we not only confirmed 18
significant SNVs but also identified two novel recurrent
mutations in the CUL3 and RBPJ genes. CUL3 encodes cullin 3,
a member of a ubiquitin ligase complex that functions in the
oxidative stress response pathway. This gene displays frequent
deletions or mutations in SCC47,48. RBPJ encodes a
transcriptional factor regulating Notch signaling pathway,
which has been shown to be an effective therapeutic target in
various tumours45,49,50. By using this large sample size, we
generated clinical background-related mutational signatures in
ESCC. More importantly, we found that, among the six
mutational signatures, Signature E4 occurred mostly in the
transcribed DNA strand and was correlated with patients’
drinking status and the variant genotypes in ALDH2 and
ADH1B that have been associated with increased susceptibility
to ESCC by genome-wide association studies21,22. The
correlations between mutations in Signature E4 in ESCC and
drinking and alcohol-metabolizing genotypes further support an
important role of alcohol intake in aetiology of ESCC4,5.
In this study, we also performed functional assays to validate
the novel findings. We found that disturbing CUL3 and RBPJ
expression substantially altered the malignant phenotypes, such
as proliferation, migration and invasion in vitro in SCC cells.
Therefore, it is biologically plausible to define these two
mutations as potential driver mutations in ESCC. We also
demonstrated that knockdown of EGFR, BRD9 and PPFIA1,
which showed frequently copy-number gain at the genomic level,
significantly inhibited cancer cell proliferation, indicating that
these genes may play important oncogenic roles in ESCC.
Moreover, we found that knockdown of expression of CLPTM1L,
ATP9B, PQLC1 as well as EGFR significantly inhibited cancer cell
migration and invasion. While the effect of CLPTM1L on the
progression of cancer has been previously reported51, the
functions of ATP9B and PQLC1 in SCC cell migration and
invasion have never been reported before. These findings provide
evidence that gain of function of these genes in ESCC might serve
as therapeutic targets for ESCC treatment.
Non-coding DNA elements comprise the majority of the
genome, and mutations in these regions have not been well
characterized in ESCC. Accumulating evidence has indicated that
lncRNAs play important roles in cancer52. Mutations in lncRNAs
might cause RNA structure change or influence binding affinity
to proteins. It has been shown that NEAT1, which forms
SWI/SNF chromatin-remodelling complex53, participates in
carcinogenesis of various types of cancer27–30, consistent with
our finding that NEAT1 is significantly mutated in ESCC. On the
other hand, mutations in gene regulatory regions might change
the binding affinity of miRNAs or transcriptional factors and
result in alterations of gene expression. In this study, we indeed
found that the mRNA expression levels in samples with
mutations in 30UTR of FOXJ3 and CLOCK had significantly
altered compared with samples without the mutations. FOXJ3
and CLOCK have been reported to be involved in
tumorigenesis54,55, which is in line with our findings. However,
due to relative small sample size and low coverage of WGS in this
study, further validation of the identified mutations in non-
coding regions is needed.
Our present study has some limitations. First, the functional
roles of the four mutated noncoding RNAs and their mutations
are not clear yet and need to be addressed by further functional
studies. Second, we identified several genes (for example, LRPIB,
FHIT and TTC28) with high frequency of SV but the expression
of these genes was not significantly changed. Although this
phenomenon has also been observed in the WGS study of
hepatocellular carcinoma and other WES studies28,38,56, further
studies are warranted to elucidate the potential reasons, such as
whether the SV occurs only in one allele but the gene expression
is complemented by the other allele, whether there exist other
mechanism such as SNV, CNV or DNA methylation, all of which
may influence the expression of the affected genes, and whether
these SVs may occur only in part of the whole gene region leading
to a change of structure but not the expression of the gene.
In conclusion, this study characterized the genomic alterations
in ESCC through WGS and integrative analysis. We have not only
confirmed some previously reported findings but also identified
several novel genomic alterations in ESCC. These results establish a
comprehensive genomic landscape of ESCC and provide potential
targets for precision treatment and prevention of the cancer.
Methods
Collection of biospecimens. ESCC were obtained from individuals (N¼ 94)
recruited at the Cancer Hospital, Chinese Academy of Medical Sciences
(Beijing, China) and Zhejiang Cancer Hospital (Hangzhou, China) between
2010 and 2014. All the individuals with ESCC were unrelated Han Chinese whose
demography characteristics and clinical information were obtained from medical
records. Informed consent was obtained from each participant, and this study was
approved by the Institutional Review Board of the Chinese Academy of Medical
Sciences, Cancer Institute and Zhejiang Cancer Hospital. All the individuals
underwent oesophagectomy and received no chemotherapy or radiotherapy before
surgery. The biospecimens, including tumour tissues, adjacent normal oesophageal
tissues (Z5 cm from tumour site) and blood samples from each individual, were
collected at the time of treatment.
Collection of clinical data. Clinical data for each individual were collected, which
included gender, age at diagnosis, ethnicity, smoking status, drinking status,
tumour site in the oesophagus, tumour stage and tumour grade. Individuals who
smoked an average of o1 cigarette per day and for o1 year in their lifetime were
defined as nonsmokers; otherwise, they were defined as smokers. Individuals were
classified as drinkers if they drank at least twice a week and continuously for at least
1 year during their lifetime; otherwise, they were defined as nondrinkers. Tumour
TNM staging components including Tumour, Node and Metastasis were reviewed
by at least three pathologists and defined according to the American Joint
Committee on Cancer Seventh edition. Previous studies have investigated
numerous molecular and clinical risk factors without validation for potential
clinical applications. Therefore, few patients had documentation for any molecular
biomarkers for further analyses. Distributions of selected characteristics among the
94 patients are shown in Supplementary Table 6.
Verification of histopathologically diagnosis. All the tumours were histo-
pathologically classified as ESCC. Tumour samples and distant normal tissues were
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embedded in optimal cutting temperature medium and histological sections
stained with haematoxylin and eosin were reviewed by at least two pathologists for
quality assurance that tumour specimens contained an average of 75% tumour cell
nuclei witho20% necrosis, whereas normal specimens contained no tumour cells.
Processing of biospecimens. DNA and RNA from tissue samples were extracted
using the Allprep DNA/RNA Kit (Qiagen) while blood DNA was extracted using
QiaAmp Blood Midi Kit (Qiagen). DNA samples were quantified by Picogreen
fluorescence assay and resolved by 1% agarose gel electrophoresis to confirm high
molecular weight fragments. A custom Sequenom SNP panel was utilized to verify
that tumour DNA and germline DNA was derived from the same patient. One
microgram of DNA from each tumour and normal tissue was sent to Qiagen for
REPLI-g whole-genome amplification using a 100mg reaction scale. RNA was
quantified by Abs260 using an UV spectrophotometer and then analysed via the
RNA6000 nano assay (Agilent) for determination of an RNA Integrity Number.
We discarded samples with RNA Integrity Number o7.0 (Supplementary Fig. 1).
Aliquots of DNA and RNA were shipped to the sequencing centre for all sub-
sequent testing.
Genomic mutation detection and analysis. High-coverage WGS sequencing of
DNA samples from 94 ESCC was performed on the Illumina HiSeq X Ten System.
The sequence reads were aligned to the genome (hg19) using the bwa mem
(v0.7.4)57 with default parameters. Duplicates were removed using Picard. The
somatic mutations were called by Strelka58. Final somatic calls were filtered to
require a quality score of430 and were further annotated by snpEff and snpSift59.
Non-negative matrix factorization was applied to the 96-substitution pattern and
the contribution of each signature to each mutation catalogue was estimated by an
algorithm from the Wellcome Trust Sanger Institute19. We performed PCR-based
Sanger sequencing on a total of 105 putative somatic mutations identified in this
study. PCR primers were designed using Primer3 to amplify a 100- to 700-bp
region containing each mutation (Supplementary Data 15).
We carried out significance analysis of mutations using the MutSigCV
algorithm22, as elaborated in several genome projects, with qo0.5 being considered
significant in our data and qo0.1 being considered significant in the combined
analysis. Genes mutated in o1% of samples or expressed (RSEM value of RNA
sequencing is not zero) in o10% of samples were considered non-ESCC driver
genes. For mutations in the non-coding regions, we performed analysis on
promoters and UTRs of coding genes (N¼ 20,014) and lncRNAs (N¼ 7,747)
annotated by Gencode v24 (ref. 26). The promoter is defined as the region between
upstream 2 kb and downstream 250 bp from any transcription start site of a coding
transcript gene and excluded any overlap with the coding regions. A regional
recurrence testing approach was used to search for significant regions that were
mutated more frequently than expected by chance16. To avoid false positive, only
regions with FDR qo0.05 and43% mutation samples were considered significant.
Mutual exclusive analysis was performed using gitools (v2.2.2)60. All statistical
analyses were performed in R using standard implementation.
We analysed copy number using SynthEx (unpublished, http://chenmengjie.
github.io/SynthEx). In brief, 100 kb bin counts data (segment data) were generated
using BEDTools61. The read ratios were calculated using the ‘synthetic normal’
strategy described in SynthEx by averaging normal samples sequenced by the same
protocol to reduce unwanted variation contributed by local characteristics and
factors in sequencing process. A trending filter procedure was applied to segment
the genome. The log2 ratios for segments were finally corrected by purity estimate
from SynthEx. To infer recurrently focal peak in amplified or deleted genomic
regions, we used the GISTIC algorithm62 with copy numbers in 1 kb windows as
markers instead of SNP array probes. G-scores were calculated for genomic and
gene-coding regions based on the frequency and amplitude of each gene with
amplification or deletion. A significant CNV region was defined as having
amplification or deletion with an FDR q value o0.25. For the arm-level analysis,
chromosomal arms were considered to be altered if at least 66% of the arm
(all_thresholded.by_genes.txt file from the GISTIC output) was lost or gained.
We used Meerkat63 and Delly2 (ref. 64) to detect somatic SVs. Since the mean
insert size is o300 bp and our WGS data are 150 bp paired-end reads, we first
truncated the reads to 100 bp to avoid overlapping of the read pairs. Possible false
positives were then filtered using a realignment procedure based on a hidden
Markov Model and realigns discordant reads against a set of candidate sequences,
including the local reference sequence and sequences obtained by inserting SNPs
and indels implied in the short reads mapped nearby65. We then merged Meerkat
and Delly2 predictions: if the breakpoints of a SV are within 500 bp of those of
another SV, the two SVs are merged and viewed as one single SV. Complex
rearrangements are called by ShatterSeek66 and a genome having complex
rearrangement is called if P value o0.01. All genes were annotated and enriched
with Kyoto Encyclopedia of Genes and Genomes pathway using DAVID (v6.8)67.
RNA expression analysis. Methods for RNA sequencing and data processing
were based on the TCGA RNA-Seq protocol38. Briefly, total RNA of each sample
was extracted, prepared into Illumina TruSeq mRNA libraries and sequenced by
Illumina HiSeq2000 with a total of 10Gb data. RNA reads were aligned to the hg19
genome assembly using Mapsplice68. To confirm SNVs reported in the WGS DNA
samples, we applied UNCeqR69 to call somatic variants from RNA-Seq data. Gene
expression using RSEM47 was quantified for the transcript models corresponding
to the TCGA GAF2.1 and normalized to a fixed upper quartile of total reads within
the sample. For further gene-level analysis, expression values were the RSEM value
added by 1 and then log2 transformed. Principal component analysis (PCA) with
R standard implementation was conducted in ESCC and paired normal tissues and
batches. We were blinded to the group allocation during the experiments. The plots
of the first two principal components are shown in Supplementary Fig. 22. Based
on these figures, the samples are clearly divided into two groups, tumour and
normal tissue, according to the second component. It is reassuring that none of the
tumour or normal tissues had been contaminated, swapped or misplaced. None of
the batches in tumour or normal tissues showed batch effects in PCA plots.
We further performed regression analysis using batch ID and first 10 PCs and none
of the regression coefficients was significant (all P40.05), suggesting that technical
batch effects in our data sets were reasonably small and thus unlikely to influence
high-level analyses. Genes with Po0.05 (paired t-test) and expression fold change
(41.2 or o0.8) in tumours comparing with normal tissues were considered
significantly differently expressed. To estimate the effect of copy-number change of
each gene on its mRNA expression, Spearman’s correlations were calculated
between gene copy number and its corresponding mRNA expression. Correlations
were considered significant and positive when Po0.05 and r40.3.
Comparison of ESCC with other types of cancer. To compare SNV pattern of
ESCC with other types of cancers, WES data of 384 HNSCC and 179 LUSCC
samples from the TCGA project and 141 EAC samples from the TumorPortal
database70 were obtained. To compare CNV and RNA patterns, CNV and RNA
data in 94 ESCC, 519 HNSCC, 512 LUSCC, 439 STAD and 79 EAC samples were
obtained from the TCGA project. We used the Hierarchical Clustering to assess the
SNV, CNV and RNA differences across different cancer types. PCA method was
also used to assess the CNV and RNA differences. For the Hierarchical Clustering,
mutation frequency or arm-level data were hierarchically clustered in R based on
Euclidean distance using the Ward’s method and RNA data were hierarchically
clustered using the average linkage algorithm with 1 minus Pearson correlation
coefficient as the dissimilarity measure.
Cell lines. ESCC cell lines, KYSE30, KYSE150 and LUSCC cell line, NCI-H520,
were cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum
(FBS). HNSCC cell line FaDu was cultured in Eagle’s Minimum Essential Medium
supplemented with 10% FBS. All cell lines were cultured in an atmosphere con-
taining 5% CO2 at 37 C. The KYSE series were generous gifts from Dr Y. Shimada
at the Kyoto University. The LUSCC and HNSCC cell lines were purchased from
the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
(Beijing, China). All cell lines used in this study were authenticated by short
tandem repeat profiling and tested for absence of mycoplasma contamination
(MycoAlert, Lonza Rockland).
siRNA transfection. We mixed three siRNAs targeting the same gene as the
siRNA-mix. Cells were transfected with siRNA-mix and Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. In brief, 24 h before
transfection, cells were plated onto a six-well plate (Corning, USA) at 30–50%
confluence. The next day, cells with about 90% confluence were transfected with
2 ml Lipofectamine 2000 and 50 nM siRNA control or corresponding siRNA mix.
After transfection, cells were incubated at 37 C for 6 h and the medium was then
replaced with fresh medium containing 10% FBS. After 48–72 h, cells were
collected for further experiments. All siRNA oligos were purchased from
GenePharma and their sequences are shown in Supplementary Data 16.
Quantitative real-time PCR. Total RNA from cells was extracted with TRIzol
(Invitrogen) according to the manufacturer’s instruction. First-strand cDNA was
synthesized using the PrimeScript 1st Strand cDNA Synthesis Kit (Takara). Rela-
tive RNA expression levels determined by quantitative real-time PCR were mea-
sured using the SYBR Green method on an ABI Prism 7,900 sequence detection
system (Applied Biosystems) with SYBR Premix Ex Taq (Takara, Japan), 50 ng
cDNA and 1 mM gene specific primers in a 25 ml reaction mixture. Reactions were
performed with an initial 30-s denaturation step at 95 C, followed by 40 cycles of
95 C for 5 s and 60 C for 30 s. Independent experiments were done in triplicate.
GAPDH was employed as an internal control. All gene specific primers are shown
in Supplementary Table 7.
Cell proliferation and migration or invasion assays. Cells were plated in 96-well
plates and each well contains 2,000 cells in 200ml cell suspension after transfection
with siRNA-mix. Cell numbers were measured with CCK-8 (Dojindo) at 24, 48, 72
and 96 h after incubation. The migration and invasion ability of each cell line was
evaluated, respectively, using the 24-well chambers (8 mm pore size; Corning). For
migration assays, 5–10 104 cells in 150ml serum-free RPMI 1640 medium were
added into the upper chamber. For invasion assays, cells were added after coating
filters with matrigel. RPMI 1640 medium with 20% FBS was used as a chemoat-
tractant in the lower chamber. After 24-h incubation at 37 C, cells were fixed in
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methanol and stained with 0.5% crystal violet. After removing cells on the upper
chamber, cells that migrated to the bottom side of the membrane were counted.
Comparison with siRNA control was performed with unpaired t-test.
Data availability. The raw sequencing data of this study have been deposited
in the Genome Sequence Archive of Beijing Institute of Genomics, Chinese
Academy of Sciences (http://gsa.big.as.cn/) with accession number PRJCA000354.
Data that support the findings of this study are available from TCGA database
(http://cancergenome.nih.gov) and TumorPortal (http://www.tumorportal.org)
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